A Novel Small NPC1 Promoter Enhances AAV-Mediated Gene Therapy in Mouse Models of Niemann–Pick Type C1 Disease
Cells · 2023
DOI: 10.3390/cells12121619 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Michael Paul Hughes und 8 weiteren Autor:innen. Beteiligte Einrichtung: UCL School of Pharmacy, University College London, London WC1N 1AX, UK. Hauptthemen laut MEDLINE: Genetic Therapy, Intracellular Signaling Peptides and Proteins, Niemann-Pick C1 Protein, Niemann-Pick Disease, Type C. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Wellcome Trust, UK Medical Research Council.
Abstract (Originalsprache)
Niemann–Pick disease type C1 (NP-C) is a prematurely lethal genetic lysosomal storage disorder with neurological and visceral pathology resulting from mutations in the NPC1 gene encoding the lysosomal transmembrane protein NPC1. There is currently no cure for NP-C, and the only disease modifying treatment, miglustat, slows disease progression but does not significantly attenuate neurological symptoms. AAV-mediated gene therapy is an attractive option for NP-C, but due to the large size of the human NPC1 gene, there may be packaging and truncation issues during vector manufacturing. One option is to reduce the size of DNA regulatory elements that are essential for gene expression, such as the promoter sequence. Here, we describe a novel small truncated endogenous NPC1 promoter that leads to high gene expression both in vitro and in vivo and compare its efficacy to other commonly used promoters. Following neonatal intracerebroventricular (ICV) injection into the CNS, this novel promoter provided optimal therapeutic efficacy compared to all other promoters including increased survival, improved behavioural phenotypes, and attenuated neuropathology in mouse models of NP-C. Taken together, we propose that this novel promoter can be extremely efficient in designing an optimised AAV9 vector for gene therapy for NP-C.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCL School of Pharmacy, University College London, London WC1N 1AX, UK.
- Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.
ORCID-Profile: Hemanth Ramesh Nelvagal, Dave Smith, Giulia Massaro, Frances Mary Platt, Ahad Abdul Rahim
Förderung
- Medical Research Council
- Wellcome Trust
- UK Medical Research Council
- Wellcome Trust Institutional Strategic Support Fund/UCL Therapeutic Acceleration Support (TAS) Fund
- Sigrid Rausing Trust and the Jameel Education Foundation
- NIHR
Zitieren
APA
Hughes, M. P., Nelvagal, H. R., Coombe-Tennant, O., Smith, D., Smith, C., Massaro, G., Poupon-Bejuit, L., Platt, F. M., & Rahim, A. A. (2023). A Novel Small NPC1 Promoter Enhances AAV-Mediated Gene Therapy in Mouse Models of Niemann–Pick Type C1 Disease. Cells. https://doi.org/10.3390/cells12121619
Vancouver
Hughes MP, Nelvagal HR, Coombe-Tennant O, Smith D, Smith C, Massaro G, et al. A Novel Small NPC1 Promoter Enhances AAV-Mediated Gene Therapy in Mouse Models of Niemann–Pick Type C1 Disease. Cells. 2023. doi:10.3390/cells12121619
BibTeX
@article{Hughes2023,
author = {Hughes, Michael Paul and Nelvagal, Hemanth Ramesh and Coombe-Tennant, Oliver and Smith, Dave and Smith, Claire and Massaro, Giulia and Poupon-Bejuit, Laura and Platt, Frances Mary and Rahim, Ahad Abdul},
title = {A Novel Small NPC1 Promoter Enhances AAV-Mediated Gene Therapy in Mouse Models of Niemann–Pick Type C1 Disease},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12121619}
}
EUVIMED